Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease
In this real-world comparative effectiveness study, FF/UMEC/VI was associated with significantly lower rate and risk of COPD exacerbations than BUD/GLY/FORM.
Authors
- Stephen Weng (ORCID: https://orcid.org/0000-0002-5281-9590)
- François Laliberté (ORCID: https://orcid.org/0000-0003-2601-6214)
- Anabelle Tardif‐Samson (ORCID: https://orcid.org/0009-0009-5118-1909)
- Julien Boudreau
- Chris Compton (ORCID: https://orcid.org/0000-0002-7564-5343)
- Rosirene Paczkowski (ORCID: https://orcid.org/0009-0001-7151-4311)
- Guillaume Germain (ORCID: https://orcid.org/0000-0002-4525-7673)
- Stephen G. Noorduyn (ORCID: https://orcid.org/0000-0002-5936-5579)
- Sergio Forero-Schwanhaeuser
- David M. Mannino (ORCID: https://orcid.org/0000-0003-3646-7828)
- Patrick Gravelle (ORCID: https://orcid.org/0000-0001-6296-8795)
Institutions
- University of Kentucky (US)
- Age UK (GB)
- GlaxoSmithKline (United States) (US)
- COPD Foundation (US)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Impact (CA)
- McMaster University (CA)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2024-12-28
- DOI
- https://doi.org/10.1007/s12325-024-03088-1
- Citations
- 11
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 4.61